Indivior’s opioid addiction treatment has been exposed to generic competition. Can the drugmaker fight back? Alice Gråhns reports.
Recent articles Indivior Plc Ord Usd2.00
Drugmaker Indivior is on the up, while retailer Next, once a favourite with investors, has lost its way.
Showing page 1 of 2Indivior Plc Ord Usd2.00 overview